
Novartis exec sold off shares before Zolgensma data scandal was revealed
pharmafile | August 19, 2019 | News story | Sales and Marketing | AveXis, Novartis, Shares, Zolgensma, pharma, stock market
An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA made the public aware that data had been manipulated in trials of Zolgensma.
As revealed in a Swiss stock exchange filing from 19 July, a member of Novartis’ board of directors sold shares on the Swiss stock exchange less than three weeks before the FDA published a press release warning the public of faults in the data used for the approval of $2.1 million gene therapy Zolgensma on 6 August.
Novartis notified the FDA of faults in the data in June. The firm had first learned of the manipulation in March and had completed an internal investigation by early May. Shares in Novartis fell by as much as 3% on announcement of the news in early August.
Speaking to Reuters a spokesperson for Novartis said: “As is usual in such cases, the transaction was thoroughly checked beforehand and then approved accordingly. The person in question was not in possession of relevant material information.”
Louis Goss
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …






